Scientific Session

Rebuttal #2

Speaker(s)

• 

  Janet Pope, MD, FRCPC, MPH

  University of Western Ontario
  London, ON, Canada

  Disclosure: Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Actelion: Consultant (Ongoing); Amgen: Consultant (Ongoing); Bayer: Consultant (Ongoing); Boehringer Ingelheim: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Eicos Sciences: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Emerald: Consultant (Ongoing); Gilead: Consultant (Ongoing); Janssen: Consultant (Ongoing); merk: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Roche: Consultant (Ongoing), Grant/Research Support (Ongoing); Sandoz: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Seattle Genetics: Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• HE

  Hani El-Gabalawy, MD, FRCPC

  University of Manitoba
  Winnipeg, MB, Canada

  Disclosure: Disclosure(s): No financial relationships with ineligible companies to disclose